KAT6 is an emerging target in hormone sensitive breast tumors and other cancers. Overexpression of KAT6A/B correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer – the most common subtype. The molecule has demonstrated strong preclinical activity. Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.… Continue reading Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications
Category: Newswire
The Colossal Impact: 2023 Allocation of Funds Raised for Charity Through Online Competitions
PHOENIX , Jan. 4, 2024 /PRNewswire/ — Colossal Management, a pioneering force in changing the landscape of fundraising through online competitions, announces the allocation of over $23 million in donation funds raised in 2023. Colossal’s unique approach to fundraising benefits both charities and competitors, bringing together communities to support important causes. Through various competitions, Colossal has… Continue reading The Colossal Impact: 2023 Allocation of Funds Raised for Charity Through Online Competitions
Retail Ready Packaging Market Size to Grow USD 107.8 Billion by 2031 at a CAGR of 5.1% | Valuates Reports
BANGALORE, India, Jan. 4, 2024 /PRNewswire/ — Retail Ready Packaging Market is Segmented By Product Type (Die cut display containers, Corrugated cardboard boxes, Shrink wrapped trays, Folding cartons, Others), By Material (Plastic, Paper & Paperboard, Others), By Application (Food & Beverage, Pharmaceuticals, Electronics, Personal Care & Cosmetics, Other). The Global Retail Ready Packaging Market is projected… Continue reading Retail Ready Packaging Market Size to Grow USD 107.8 Billion by 2031 at a CAGR of 5.1% | Valuates Reports
NewsBreak launches Brand Suitability Controls for Advertisers
Brands can now have more control over the environment adjacent to their advertisement MOUNTAIN VIEW, Calif., Jan. 4, 2024 /PRNewswire/ — NewsBreak, the nation’s leading AI-powered local news and information platform with 60M MAU, launched Brand Suitability Controls, a new suite of tools to help brands ensure that content adjacent to advertisements meets their brand’s specific… Continue reading NewsBreak launches Brand Suitability Controls for Advertisers
PR Newswire Unveils New Partnership with Map Your Show for CES 2024
NEW YORK, Jan. 4, 2024 /PRNewswire/ — PR Newswire, the industry leader in press release distribution, is simplifying PR communications for CES exhibitors through a strategic partnership with Map Your Show, a leading event management and technology solutions provider. This exciting collaboration will streamline the press release distribution and ordering process for exhibitors, allowing them to… Continue reading PR Newswire Unveils New Partnership with Map Your Show for CES 2024
Dr. John N. van den Anker Named New Editor-in-Chief of The Journal of Clinical Pharmacology
ASHBURN, Va., Jan. 4, 2024 /PRNewswire/ — The American College of Clinical Pharmacology® (ACCP) proudly announces the appointment of Dr. John N. van den Anker, MD, PhD, FAAP, FCP, as the new Editor-in-Chief of The Journal of Clinical Pharmacology (JCP). A distinguished neonatal and pediatric clinical pharmacologist, Dr. van den Anker currently holds the Evan… Continue reading Dr. John N. van den Anker Named New Editor-in-Chief of The Journal of Clinical Pharmacology
VNET INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In VNET To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in VNET stock or options between April 8, 2022 and February 15, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/VNET. There is no cost or… Continue reading VNET INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In VNET To Contact Him Directly To Discuss Their Options
CHARGEPOINT INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ChargePoint To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 investing in ChargePoint securities between June 1, 2023 and November 16, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/CHPT. There is no cost or obligation to… Continue reading CHARGEPOINT INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ChargePoint To Contact Him Directly To Discuss Their Options
BEAUTY HEALTH INVESTOR DEADLINE APPROACHING
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Beauty Health To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 investing in Beauty Health securities between May 10, 2022 and November 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner… Continue reading BEAUTY HEALTH INVESTOR DEADLINE APPROACHING
Thomson Reuters Fourth-Quarter and Full-Year 2023 Earnings Announcement and Webcast Scheduled for February 8, 2024
Conference call and webcast scheduled for 9 a.m. EST TORONTO, Jan. 4, 2024 /PRNewswire/ — Thomson Reuters (NYSE, TSX: TRI) announced today its fourth-quarter and full-year 2023 earnings will be issued via news release on Thursday, February 8, 2024. Steve Hasker, president and chief executive officer, and Mike Eastwood, chief financial officer, will host a… Continue reading Thomson Reuters Fourth-Quarter and Full-Year 2023 Earnings Announcement and Webcast Scheduled for February 8, 2024